Put companies on watchlist
BB BIOTECH AG
ISIN: CH0038389992
WKN: A0NFN3
Curious about what AI knows about BB Biotech? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

BB BIOTECH AG · ISIN: CH0038389992 · EQS - adhoc news (75 News)
Country: Switzerland · Primary market: Switzerland · EQS NID: 2174222
25 July 2025 07:00AM

BB Biotech AG publishes its interim report


EQS-Ad-hoc: BB BIOTECH AG / Key word(s): Half Year Report
BB Biotech AG publishes its interim report

25-Jul-2025 / 07:00 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

July 25, 2025

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at June 30, 2025, which covers the results of its business activities for the first six months of 2025.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended June 30, 2025, amounted to CHF 341 mn (gain of CHF 173 mn in H1 2024). In the second quarter a loss of CHF 100 mn (loss of CHF 87 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

The interim report as at June 30, 2025, is available under report.bbbiotech.ch/Q225 or www.bbbiotech.com.


For further information:
Bellevue Asset Management AG
Theaterstrasse 12, 8001 Zurich, Switzerland, Phone +41 44 267 67 00

Head BB Biotech
Dr. Christian Koch

Head Investor Relations
Rachael Burri*

Investor Relations
Claude Mikkelsen

E-Mail: ir@bbbiotech.com
Phone: +41 44 267 67 05

Media Relations
Tanja Chicherio, tch@bellevue.ch


www.bbbiotech.com

*Start on August 1, 2025



Company profile 
BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world’s largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.



End of Inside Information

25-Jul-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 2174222

 
End of Announcement EQS News Service

2174222  25-Jul-2025 CET/CEST

Visual performance / price development - BB BIOTECH AG
Smart analysis and research tools can be found here.
MIC: XSWX

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.